Table of contents


On 14 September 2012, orphan designation (EU/3/12/1036) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt for the treatment of familial chylomicronaemia syndrome (type-I hyperlipoproteinaemia).

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2018 on request of the Sponsor.

Key facts

Active substance
Trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt
Disease / condition
Treatment of familial chylomicronaemia syndrome (type-I hyperlipoproteinaemia)
Date of first decision
EU designation number

Sponsor's contact details

Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom
Tel. +41 61 324 11 11 (Switzerland)

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating